![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Heritage Mining Ltd | CSE:HML | CSE | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.005 | 9.09% | 0.06 | 0.06 | 0.07 | 0.06 | 0.055 | 0.055 | 480,000 | 20:12:56 |
RNS Number:5319J Henderson Morley PLC 02 April 2003 HENDERSON MORLEY PLC 2 April 2003 ICVT - PHASE II STUDY STARTS The Directors of Henderson Morley are pleased to announce that the Phase ll study to examine the use of Ionic Contra Viral Therapy ("ICVT") against a genital infection known as VIN* has now started and the first patients have been successfully recruited. The study is under the supervision of Professor Alison Fiander, a leading expert in the field of Gynaecology, at the University Of Wales, College Of Medicine. Preliminary results are expected by the end of this year. The data created by this study will be used to attract further commercial partners for the ICVT platform. This open label**, dose-escalating*** Phase ll study is directed against VIN, which is caused by the Human Papilloma Virus, typically types 16 and 18. It affects the genital tract of women and these viruses are also associated with cancer of the vulva and vagina, and cancer and pre-cancer of the cervix. The only treatments generally used against VIN are surgical - either removing or destroying the infected tissue by laser or conventional surgery. This study will examine the effects of ICVT when applied to infected tissue and has been described by Professor Fiander's team as "a very important study". The Company believes success in this study should have important implications for the treatment of these other conditions. Cancer of the cervix is the second most common cancer in women on a global basis and causes an estimated 450,000 new cases and 200,000 deaths annually****. More than 2.5 million women are diagnosed with low grade CIN (Cervical Intra-epithelial Neoplasia or mild to moderate pre-cancerous changes)and a further 200,000-300,000 are diagnosed with high grade dysplasia (more severe pre-cancerous changes) each year in the USA alone. Worldwide the incidence is much higher. (WHO figures) *VIN or Vulval Intraepithelial Neoplasia is a disease of the female genital tract caused by strains of HPV which, if untreated, may become cancerous. It is unclear from previous studies what proportion of patients with VIN become cancerous. Most patients with this condition will have symptoms of pain and discomfort. **.Open label studies are when the patient and the doctor treating them are both aware of the drugs being used in the study. *** Dose escalating studies are when the dose of drug being used to treat the patient is gradually increased from very low doses to higher doses, depending on the clinical response. ****Source: National Network of STD/HIV Prevention Training Centers Curriculum Committee figures ENDS Copies of this announcement will be available free of charge to the public at the Company's registered office at Metropolitan House, 2 Salisbury Road, Moseley, Birmingham, B13 8JS and at the offices of Brewin Dolphin Securities Ltd, 34 Lisbon Street, Leeds LS1 4LX for 14 days. Enquiries: HENDERSON MORLEY PLC Tel: 0121 442 4600 Andrew Knight, Chairman BREWIN DOLPHIN SECURITIES LTD Tel: 0113 241 0126 Neil Baldwin BARNES AND WALTERS LTD Tel: 020 7430 1600 Maxine Barnes Mobile 07860 489571 Editor's Notes Human Papillomavirus ("HPV") is one of the most common causes of Sexually Transmitted Disease ("STD") in the world. Experts believe that as many as 24 million Americans are infected with one of the 60-plus known types of HPV, with this number appearing to be on the increase. At present there is no cure for HPV, and no prevention besides abstaining from skin-to-skin contact with the infected areas. Although a variety of treatments are available, they typically act by killing the cell in which the virus lives and not by directly killing the virus itself. This means the side effects of treatment are often severe. These treatments can take various forms; for example, chemical procedures, freezing or laser treatment. In extreme cases surgery may be required to remove warts that have not responded to other treatments. A person infected with HPV may exhibit no visible symptoms; the virus may lie dormant for many years. This can make it very difficult to identify an infection, prevent transmission to others and reduce the chance of complications. While many low-risk types of HPV cause little or no discomfort, some high-risk types of HPV are very aggressive; HPV is responsible for over 99% of all cervical cancers and over 50% of other anogenital cancers. HPV is also the cause of genital warts that, with at least 1 million new cases diagnosed in the USA alone every year, is the fastest growing viral STD. Genital warts are spread by sexual contact with an infected partner and are very contagious, with approximately two-thirds of people who have had sexual contact with an infected person developing warts of their own. Genital warts are particularly hazardous to pregnant women, possibly causing problems during delivery. It is also rare - but not unheard of - for infants born to women with genital warts to develop the potentially life-threatening condition Laryngeal Papillomatosis (warts in the throat). A doctor can usually diagnose genital warts by visual examination, but a Pap smear test may be necessary to identify the presence of a cervical HPV infection. Typically, a pre-cancerous cervical disease such as this is readily treatable using destructive methods such as laser or cryotherapy. This information is provided by RNS The company news service from the London Stock Exchange END RESUUUUGCUPWGUP
1 Year Heritage Mining Chart |
1 Month Heritage Mining Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions